Adcock Richard 4
4 · ImmunityBio, Inc. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
Adcock Richard
DirectorCEO & President
Transactions
- Exercise/Conversion
Common Stock
2025-12-31+34,483→ 368,901 total - Tax Payment
Common Stock
2025-12-31$1.98/sh−17,510$34,670→ 351,391 total - Exercise/Conversion
Restricted Stock Units
2025-12-31−34,483→ 51,731 total→ Common Stock (34,483 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
- [F2]On December 31, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2025 was the settlement price used to calculate the shares withheld.
- [F3]Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.